MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
Go here to see the original:
Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call
Related Post
- NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - February 24th, 2025
- Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial... - February 24th, 2025
- Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million - February 24th, 2025
- Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 - February 24th, 2025
- Ensho Therapeutics Announces Presentation of Data Highlighting NSHO-101 as a Once-Daily Oral Agent for the Potential Treatment of Inflammatory Bowel... - February 24th, 2025
- Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration - February 24th, 2025
- Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 - February 24th, 2025
- Dogecoin Cash, Inc. (OTC:CBDS) Announces Strategic Expansion of Crypto Holdings with Acquisition of 420 Million Dogecoin Cash ($DOG) - February 24th, 2025
- Ipsen S.A. publishes its 2024 consolidated financial statements - February 24th, 2025
- Fortrea to Add Erin L. Russell to Board of Directors - February 24th, 2025
- Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned - February 24th, 2025
- Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative... - February 24th, 2025
- eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. - February 24th, 2025
- Dr. Gregory George MD PhD Joins Mesoblast Board - February 24th, 2025
- IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference - February 24th, 2025
- Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease - February 24th, 2025
- OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO - February 24th, 2025
- Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4] - February 24th, 2025
- Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - February 24th, 2025
- Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association... - February 15th, 2025
- ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences - February 15th, 2025
- Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - February 15th, 2025
- Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination - February 15th, 2025
- Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® - February 15th, 2025
- IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - February 15th, 2025
- Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update - February 15th, 2025
- Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 - February 15th, 2025
- Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) - February 15th, 2025
- Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency - February 15th, 2025
- Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity - February 15th, 2025
- Entero Therapeutics Appoints Richard Paolone as CEO - February 15th, 2025
- NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation - February 15th, 2025
- Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 15th, 2025
- Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference - February 15th, 2025
- Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results - February 15th, 2025
- Edesa Biotech Reports Fiscal 1st Quarter 2025 Results - February 15th, 2025
- Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older - February 15th, 2025
- Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision - February 15th, 2025
- PacBio Grants Equity Incentive Award to New Employee - February 15th, 2025
- Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program - February 7th, 2025
- Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales - February 7th, 2025
- Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity - February 7th, 2025
- North Texas Took Center Stage at Advanced Therapies Week 2025, Highlighting Innovation and Collaboration in Life Sciences - February 7th, 2025
- BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors - February 7th, 2025
- GUERBET : 2024 revenue. - February 7th, 2025
- Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - February 7th, 2025
- Shareholding declaration Valneva SE - January 2025 - February 7th, 2025
- Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital - February 7th, 2025
- CARBIOS is pleased that the European Commission has authorised the ‘Circular Economy’ State aid scheme - February 7th, 2025
- 60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - February 7th, 2025
- Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 7th, 2025
- Senseonics Completes CE Mark Submission for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor - February 7th, 2025
- Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board - February 7th, 2025
- Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative... - February 7th, 2025
- GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025 - February 7th, 2025
- PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli - February 7th, 2025
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - February 7th, 2025
- Press Release: Execution of a share buyback agreement for up to €2 billion - February 7th, 2025
- Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors - February 7th, 2025
- Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - November 27th, 2024
- Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference - November 27th, 2024
- Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference - November 27th, 2024
- Fate Therapeutics to Present at Upcoming December Investor Conferences - November 27th, 2024
- Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference - November 27th, 2024
- 89bio to Participate in the 7th Annual Evercore HealthCONx Conference - November 27th, 2024
- Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024 - November 27th, 2024
- Fulcrum Therapeutics to Participate in Upcoming December Conferences - November 27th, 2024
- Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 27th, 2024
- PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024 - November 27th, 2024
- Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO - November 27th, 2024
- Fortrea to Present at the Citi Global Healthcare Conference - November 27th, 2024
- NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel - November 27th, 2024
- Fortrea to Present at the Evercore HealthCONx Conference - November 27th, 2024
- ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference - November 27th, 2024
- Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 27th, 2024
- Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference - November 27th, 2024
- Idorsia enters into exclusive negotiations for global rights to aprocitentan - November 27th, 2024
- Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of... - November 27th, 2024
- 142,701 Orion Corporation A shares converted into B shares - November 27th, 2024
- Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant... - November 3rd, 2024
Tags: